TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03844841
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced via the continuous infusion of propofol using a target-controlled infusion (TCI) pump. The effect-site propofol concentration will be initially set to 1.5 µg/ml, unless the patient is already sedated by fentanyl. Subsequently, an effect-site propofol concentration of 1 µg/ml will be chosen adjusted stepwise (using steps of 0.3 µg/ml) to reach a target score of 2-3 on the MOAA/S scale. In case of pain fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
Study: NCT03844841
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced with a loading dose of dexmedetomidine (0.8 µg/kg) over 10 minutes. The maintenance dexmedetomidine dose is adjusted to the appropriate sedation criteria for CA (0.4 µg/kg/h) and for a target score of 2-3 on the MOAA/S scale. In case of pain, additional fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
Study: NCT03358212
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle.Patients were instructed to take calcium supplements orally every day and avoid any oral operation during treatment
Study: NCT02788136
Drug: human chorionic gonadotropin
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU
Study: NCT00294996
Drug: Myocet
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01206465
Drug: pralatrexate
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01448174
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:~* atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or~* placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks.
Study: NCT00057811
Drug: rasburicase
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00057811
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or orally
Study: NCT00057811
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or orally
Study: NCT00057811
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT00057811
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03409744
Drug: evinacumab
Normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous (IV) administration
Study: NCT00057811
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01093768
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01093768
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04039880
Drug: Olorofim
Normalized name: Olorofim
DrugBank: Olorofim (DB15245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose (120 mg, 3.7 MBq)
Study: NCT00290082
Drug: loxapine, midazolam
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
Study: NCT00290082
Drug: Loxapine
Normalized name: Loxapine
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loxapine 1 mL / 10 kg
Study: NCT00290082
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 1 mL / 10 Kg
Study: NCT01248780
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
Study: NCT02460510
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02434952
Drug: Dihydroartemisinin piperaquine (DHA PP)
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02434952
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00649129
Drug: Oxybutynin Chloride ER Tablets 10 mg
Normalized name: oxybutynin chloride Extended Release Oral Tablet
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x10mg, single dose fasting
Study: NCT02320721
Drug: Insulin Glargine (HOE901 - U300)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
Study: NCT02320721
Drug: Insulin Glargine (HOE901 - U100)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
Study: NCT00110682
Drug: Imiquimod used as an adjunct to cryotherapy
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01854814
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
Study: NCT01854814
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maximum tolerated labeled dose of Losartan
Study: NCT00798915
Drug: Glucose-dependent Insulinotropic Polypeptide (GIP)
Normalized name: Heme iron polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
Study: NCT00798915
Drug: Xenin-25
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
Study: NCT00798915
Drug: Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Normalized name: GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
Study: NCT01227577
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
Study: NCT00001566
Drug: indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose, 350 mg/m\^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.
Study: NCT00253136
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00853762
Drug: Atacicept 25 mg
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Study: NCT00853762
Drug: Atacicept 75 mg
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Study: NCT00853762
Drug: Atacicept 150 mg
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Study: NCT01883804
Drug: Methyldopa
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
Study: NCT00853762
Drug: Atacicept 150 mg
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Study: NCT00827320
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg tablet
Study: NCT02502097
Drug: Gefapixant
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 50 mg tablet, administered by mouth
Study: NCT00203476
Drug: Niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00203476
Drug: Colestipol
Normalized name: Colestipol
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00203476
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01190514
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two tablets of 25 mg, single administration, under fed condition
Study: NCT01190514
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of 50 mg, single administration, under fed condition
Study: NCT01190514
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two tablets of 25 mg, single administration, under fast condition
Study: NCT01190514
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of 50 mg, single administration, under fast condition
Study: NCT00897312
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00669994
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cipro XR 500 mg tablets taken once daily
Study: NCT04487912
Drug: Tilmanocept
Normalized name: tilmanocept
DrugBank: Tilmanocept (DB15373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined peri-areolar and peri-tumoral injection of 99m-Tc Tilmanocept
Study: NCT00512317
Drug: ganaxolone
Normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: liquid suspension dosed tid
Study: NCT01013454
Drug: varenicline free base patch
Normalized name: K201 free base
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: varenicline transdermal delivery system (6.0 mg payload \[drug amount loaded in each patch\]) will be applied to the upper back over a single 24 hour period
Study: NCT00000352
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00109096
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03620370
Drug: Normobaric oxygen therapy
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should in Pre-hospital or emergency room as early as possible after diagnosed ischemic stroke and uninterrupted during other treatments including mechanical thrombolytic therapy and standard clinical treatment.
Study: NCT03693404
Drug: Bupivacaine (Marcaine)
Normalized name: bupivacaine Injection [Marcaine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
Study: NCT01667315
Drug: Bupivacaine 0,375%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
Study: NCT00947739
Drug: Camptothecin-20-O-Propionate Hydrate (CZ48)
Normalized name: SODIUM PROPIONATE HYDRATE
DrugBank: Camptothecin (DB04690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
Study: NCT00601419
Drug: Somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.~Dosage, Frequency: According to Japanese LPD, The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day.~Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration.
Study: NCT02130999
Drug: tasimelteon 20 mg capsule
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02032277
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel
Study: NCT02032277
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin
Study: NCT02032277
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib
Study: NCT02130999
Drug: tasimelteon 2 mg I.V.
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02844426
Drug: bifid triple viable capsule and pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02844426
Drug: maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01094860
Drug: Nelarabine
Normalized name: Nelarabine
DrugBank: Nelarabine (DB01280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
Study: NCT01664598
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks
Study: NCT02607631
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treated with Pembrolizumab 200 mg every 3 weeks
Study: NCT00697320
Drug: eptacog alfa (activated)
Normalized name: Eptacog alfa (activated)
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: A NON INTERVENTIONAL OBSERVATIONAL STUDY:~Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00000948
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Il-2
Study: NCT00000948
Drug: ART
Normalized name: MART1
DrugBank: Melanoma antigen recognized by T-cells 1 (DB15081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiretroviral therapy for the treatment of HIV
Study: NCT03927443
Drug: Lumigan
Normalized name: Lumigan
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one drop
Study: NCT00626288
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine 800mg t.i.d. 12 weeks
Study: NCT03439137
Drug: MT-6548
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT03439137
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT03439137
Drug: Darbepoetin alfa-matching placebo
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT02704767
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
Study: NCT02704767
Drug: Tarceva
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00106002
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
Study: NCT01733836
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00914121
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00560716
Drug: CYC116
Normalized name: CYC116
DrugBank: CYC116 (DB05198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of CYC116
Study: NCT03064035
Drug: 4-factor prothrombin complex concentrate (4FPCC)
Normalized name: Prothrombin complex concentrate
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
Study: NCT00003653
Drug: nilutamide
Normalized name: Nilutamide
DrugBank: Nilutamide (DB00665)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
Study: NCT05009355
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antioxidant
Study: NCT04456686
Drug: LY3016859
Normalized name: Ly3016859 (humanized monoclonal antibody to human tgf.alpha. and epiregulin)
DrugBank: Fepixnebart (DB19079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3016859 given IV.
Study: NCT01033396
Drug: PF-03654764
Normalized name: PF-03654764
DrugBank: PF-03654764 (DB12360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03654764 single dose 5 mg
Study: NCT01033396
Drug: Allegra
Normalized name: Allegra
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine single dose 60 mg
Study: NCT02863471
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage